Chapter Three - Sales, Scripts, and Strategy

CHAPTER THREE

Sales, Scripts, and Strategy

YOU DON’T MOVE billions of dollars in opioids by accident.

You do it with a plan.

And Purdue had one.

After OxyContin launched in 1996, the company didn’t sit back and hope doctors prescribed it. They engineered its spread. The strategy wasn’t medical, it was sales. And Purdue didn’t recruit from hospitals. They built an army of pharma reps trained like door-to-door closers.

Their mission was simple: push Oxy. Hard.

Not to cancer patients or trauma wards. That wasn’t the real market. The real target was primary care doctors. The everyday generalists who saw back pain, migraines, and post-op recovery.

These weren’t pain specialists. Many had little training in addiction medicine. But they saw patients in pain, and Purdue offered a miracle: a powerful opioid that supposedly wasn’t addictive.

The sales pitch came with free lunches, golf trips, speaker fees, and bonuses. Reps were taught to minimize concerns about abuse and emphasize “improved quality of life.” They came armed with FDA-approved brochures that danced around the truth. They celebrated doctors who prescribed high doses, often featuring them in internal newsletters. High prescribers were heroes. Low prescribers were ignored.

In 2001 alone, Purdue spent $200 million on marketing OxyContin. More than any company had ever spent promoting a Schedule II narcotic.

The results were staggering.

Prescriptions exploded. In rural areas, where coal mining and factory work left entire communities in pain, Oxy became a household name. Some doctors handed it out like candy. Others built entire practices around it. Pharmacies filled thousands of scripts a month.

Purdue called this a success story.

But it was a sales funnel with a body count.

The company tracked exactly which doctors wrote the most scripts, which regions had the highest volume, and which reps delivered the most pills. They had the data. They saw the trends. They watched the spikes in overdose deaths.

And they kept going.

When whistleblowers raised alarms, they were silenced or ignored. When internal memos warned of abuse, executives brushed them aside. When doctors were caught running pill mills, Purdue claimed it was “shocking,” even though their own sales teams had flagged the behavior years earlier.

This wasn’t a rogue drug. It was a business model.

Pain was the pitch. Oxy was the product. And human suffering was the collateral damage.

Purdue didn’t just sell pills.

They sold scripts.
They sold volume.
They sold silence.

And for a while, they sold it perfectly.